BC Platforms announced Pfizer Finland will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases. The services will be used to analyze anonymized data from Turku University Hospital and other health care providers to generate real world evidence in atrial fibrillation patients. Microsoft will provide the cloud infrastructure for indexing and accessing the information globally through the Microsoft Azure cloud platform.
"Cardiovascular diseases are the leading cause of global mortality in the world and the incidence is rising due to an aging population,” Jaakko Parkkinen, Country Medical Director at Pfizer said. “The diseases are complex and therefore we need data to fully understand and provide the best treatment outcomes for patients. We believe that combining our expertise in treatment of cardiovascular diseases with BC Platforms' advanced genomic and clinical data management solutions through BCRQUEST.COM, we can gather and analyse important real world evidence to generate optimal patient outcomes."
Pfizer and BC Platforms are both part of the FinnGen project, which is one of the largest global research projects aiming to improve human health through genetic research.